Atrial Fibrillation in Chronic Kidney Disease: An Overview

Area of Science:

• Nephrology
• Cardiology
• Internal Medicine

Background:

• Chronic kidney disease (CKD) involves kidney damage and reduced estimated glomerular filtration rate (eGFR) for over three months.
• Atrial fibrillation (AF) is a common arrhythmia that significantly impacts cardiovascular health.

Purpose of the Study:

• To discuss the causal relationship between atrial fibrillation (AF) and chronic kidney disease (CKD).
• To review the clinical impact of AF in CKD patients and explore treatment options and their complications.

Main Methods:

• Literature review of studies examining the interplay between AF and CKD.
• Analysis of shared pathophysiological mechanisms, including inflammation, RAAS activation, anemia, and uremia.
• Evaluation of pharmacological and interventional treatment modalities for AF in the context of CKD.

Main Results:

• CKD exacerbates renal dysfunction, which in turn promotes the occurrence and progression of AF.
• Shared mechanisms like inflammation, RAAS activation, anemia, and uremia contribute to the bidirectional relationship between AF and CKD.
• Treatment options for AF in CKD patients, such as antiarrhythmics, anticoagulants, and cardiac ablation, have limited usage due to potential complications.

Conclusions:

• The relationship between AF and CKD is complex and bidirectional, with each condition negatively impacting the other.
• Current treatment strategies for AF in CKD patients are often restricted by the risk of adverse events, highlighting the need for further research.
• Understanding the shared pathophysiology is crucial for developing safer and more effective therapeutic approaches for patients with both AF and CKD.